Oncolytic virus at antigen release, addressing threshold drift
Oncolytic virus (lytic antigen release) acts at the antigen release step of the cancer-immunity cycle. The failure mode is threshold drift: threshold moves out of reach of normal loading current. Capacitor sometimes fires, sometimes doesn't; unpredictable activation.
What this is
The Living Scorecard is Encounter's open record of structural predictions. Each hypothesis names a candidate intervention, where in the cycle it is predicted to act, the failure mode it is predicted to address, and the evidence available when the prediction was made.
Predictions are locked with timestamps before they can be tested. Encounter generates them daily, many more than any one person can chase, so the field can see what the framework claims structurally, ahead of the data. Some will hold. Some will be refuted. Both stay on the page. The point is that each prediction is committed before the answer is known, so the data that arrives later can confirm or refute it.
Structural argument
At the antigen release step of the cancer-immunity cycle (capacitor regime, position P1), Oncolytic virus acts via lytic antigen release. The failure mode is threshold drift: threshold moves out of reach of normal loading current. Capacitor sometimes fires, sometimes doesn't; unpredictable activation. The intervention's regime-type class lines up with the position's regime, and failure_threshold_drift belongs to that regime's failure set.
rule_r13(required) — Combinatorial candidate is grounded in R13's position-to-state table, which determines which interventions are structurally addressable at which positions.
Substrate
- Domain
- domain_cellular_biology
- Cycle
- cycle_l4_canonical
- Position(s)
- position_p1
- Failure modes
- failure_threshold_drift
Evidence at generation
"oncolytic virus" AND "cancer immunotherapy"
- PMID 37631987
Oncolytic Virus Engineering and Utilizations: Cancer Immunotherapy Perspective.
- PMID 36402738
The emerging field of oncolytic virus-based cancer immunotherapy.
- PMID 39196415
Oncolytic virus and tumor-associated macrophage interactions in cancer immunotherapy.
- PMID 38336902
An oncolytic virus-T cell chimera for cancer immunotherapy.
- PMID 38835055
Current and future immunotherapeutic approaches in pancreatic cancer treatment.
Targets: —
Not found in ChEMBL: Oncolytic virus
oncolytic virus cancer immunotherapy
- NCT04482933
Neoplasms
Primary: Efficacy (overall survival)
- NCT05205421
Advanced Solid Tumor
Primary: Incidence of adverse events
- NCT03954067
Metastatic Cancer
Primary: Dose Limiting Toxicities (DLT) - dose escalation part
- NCT02062827
Recurrent Glioblastoma Multiforme
Primary: Maximum Tolerated Dose (MTD) of M032
- NCT00348842
Metastatic Cancer
Primary: Safety and primary efficacy of NDV treatment in cancer patients who failed conventional modalities.
Status timeline
- Draft2026-05-28T23:27:38Z
Generated by combinatorial walker (v0.1.1; verb_target-aware, sub-regime failures). Awaiting operator review for the daily top-5 batch.
by system
- Published2026-05-29T06:35:42Z
Published as part of the first 5-hypothesis daily batch. Engine v0.1.1: verb_target-aware combinatorial walker, sub-regime failure pool, lowercase evidence queries. Operator review pass: kept as-is.
by raimo